AGENDA

"Treating" newly diagnosed CLL: Benefits and disadvantages of watch and wait and novel options
Apostolia-Maria Tsimberidou, MD, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX

The impact of rituximab on treatment paradigms for B-cell lymphomas
Anton Hagenbeek, MD, PhD
Academic Medical Center Amsterdam, Amsterdam, The Netherlands

Novel targeted agents and monoclonal antibodies for aggressive B-cell lymphomas
Myron S. Czuczman, MD
Roswell Park Cancer Institute, Buffalo, NY

Indolent B-cell lymphoma: New therapeutic developments
Bruce D. Cheson, MD
Georgetown University Hospital, Washington, DC

Targeting the critical pathways in multiple myeloma
Andre Goy, MD
Hackensack University Medical Center, Hackensack, NJ

The best combination regimens for newly diagnosed multiple myeloma
Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA

*Faculty disclosures will be provided at the meeting.